Our analysis strongly suggests that another cascade, consisting of highly amplified PTK2 and NFKBIE, could be strongly involved in ERBB2-related signaling in high ERRB2-expressing, trastuzumab GC patients. Here, ESRRB is linked to gastric cancer.